Singapore Biotech Startup Mirxes in Talks for $1.2B US SPAC Deal: Report

Singapore biotech company Mirxes is in early talks to go public via a blank-check company affiliated with veteran private equity healthcare investor Fu Wei, The Business Times reports, citing people familiar with the matter. The company is said to be in discussions with Summit Healthcare Acquisition, which raised $200 million in a June IPO. The combined company would reportedly be valued at $1.2 billion. Read more

Total
0
Shares
Related Posts